USA > France based Sanofi is set to acquire Bioverativ Inc. for approximately $11.6 billion

Sanofi logo For $105 per share in cash, Sanofi is set to acquire all the outstanding shares of Bioverativ representing an equity value of approximately $11.6 billion. Both biopharmaceutical companies focus on therapies for hemophilia and other rare blood disorders and the transaction was unanimously approved by Board of Directors of both Sanofi and Bioverativ. According to Olivier Brandicourt, Sanofi’s Chief Executive More …

USA > DanDrit Biotech USA, Inc. is set to acquire Enochian Biopharma Inc.

Dandrit logo Enochian Biopharma Inc. is to be acquired by DanDrit Biotech USA, Inc.  Enochian will enhance DanDrit’s research and development efforts as Enochian is developing an innovative proprietary technology in the field of HIV/AIDS. According to the acquisition terms the stockholders of Enochian shall receive: 50% of the number of shares of DanDrit’s common stock issued and outstanding upon the acquisition, More …

USA > Japan based Astellas Pharma Inc. acquires US based Mitobridge for $225 million (plus additional $225 million contingent on clinical development)

Astellas_Pharma_logo.svg Exercising its exclusive option right to acquire Mitobridge under the amended terms of the October 2013 partnership agreement governing their an R&D collaboration focused on discovering and developing novel drugs that target mitochondrial function, Astellas Pharma Inc. will now wholly own US based Mitobridge. The 2013 partnership agreements between Astellas and Mitobridge were formulated to discover and develop compounds that More …

USA > US based Agena Bioscience and Germany based Molecular Health partner for MassArray Interpretation

agena bioscience Agena Bioscience and Molecular Health have entered into strategic partnership , even though specific terms of the agreement were not disclosed, it is known that Molecular Health will use its MH guide analysis platform to interpret Agena’s MassArray system raw generated data. The firm plan to cooperate and collaborate with their respective customer bases under the partnership and is part More …

JAPAN > US based Amgen to redeem Kirin’s shares the JV Kirin- Amgen making Kirin- Amgen a wholly-owned subsidiary of Amgen

Amgen logo Both Amgen and Kirin Holdings have agreed that Kirin-Amgen’s, Kirin shares will be bought by Amgen making Kirin- Amgen a wholly- owned subsidiary of Amgen. Established in 1984 as a 50-50 joint venture between Amgen and Kirin to fund the development of EPOGEN® (epoetin alfa) and later NEUPOGEN®(filgrastim), Neulasta® (pegfilgrastim), Aranesp® (darbepoetin alfa), Nplate® (romiplostim) and brodalumab. Kirin-Amgen also holds the intellectual property of More …

AUSTRIA > Singapore based Clearbridge BioMedics is expanding in EMEA and APAC regions through partnership with twelve new distributors to 26 new countries

Clearbridge biomedics logo ClearCell® FX1 System is now available in EMEA and APAC through partnership with twelve new distributors. Partnering with an international network of distributors who are leaders in biotechnology industry with qualified professionals and high quality and reliability in their services, Clearbridge BioMedics is introducing ClearCell® FX1 System in the following countries along with the distributor for the country: Distributor Countries Axon Lab More …

AUSTRALIA > India based Strides Shasun’s subsidiary Arrow Pharmaceuticals has acquired US based Amneal Pharmaceuticals Australian operations for AUD 17 million ($13.3 million)

strides shasun logo To expand its presence in the generics market in Australia, Strides Shasun’s Australian subsidiary Arrow Pharmaceuticals has acquired the Australian operation of the US- based Amneal Pharmaceuticals for AUD 17 million ($13.3 million). According to Dennis Bastas, Chairman of Arrow Pharmaceutical, bringing Amneal’s customer base into Arrows network of pharmacies will be very beneficial for Arrow’s growth. Amneal was founded More …

SWITZERLAND > US based Johnson & Johnson expands biotech plant in Schaffhausen, Switzerland investing 22 million Swiss Francs ($22.7 million)

johnson and johnson photoshop logo USA based Johnson & Johnson expands biotech plant investing 22 million Swiss Francs ($22.7 million). The subsidiary of Johnson & Johnson Cilag AG will utilize the money to expand the biotech plant for the production of sterile products for clinical studies. Cilag AG will install modern filling machine by 2019 and it also plans to add an additional filing line More …